Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]

Kasper, Siegfried; Anghelescu, Ion-George; Szegedi, Armin; Dienel, Angelika; Kieser, Meinhard
January 2006
BMC Medicine;2006, Vol. 4, p1
Academic Journal
Background: The aim of the current study was to assess the antidepressant efficacy and safety of Hypericum perforatum (St. John's wort) extract WS® 5570 at doses of 600 mg/day in a single dose and 1200 mg/day in two doses. Methods: The participants in this double-blind, randomized, placebo-controlled, multi-center clinical trial were male and female adult out-patients with an episode of mild or moderate major depressive episode (single or recurrent episode, DSM-IV criteria). As specified by the relevant guideline, the study was preceded by a medication-free run-in phase. For the 6-week treatment, 332 patients were randomized: 123 to WS® 5570 600 mg/day, 127 to WS® 5570 1200 mg/day, and 82 to placebo. The primary outcome measure was the change in total score on the Hamilton Rating Scale for Depression (HAM-D, 17-item version) between baseline and endpoint. Additional measures included the number of responders, the number of patients in remission, and several other standard rating scales. Efficacy and safety were assessed after 2 and 6 weeks. The design included an interim analysis performed after randomization with the option of early termination. Results: After 6 weeks of treatment, mean ± standard deviation decreases in HAM-D total scores of 11.6 ± 6.4, 10.8 ± 7.3, and 6.0 ± 8.1 points were observed for the WS® 5570 600 mg/day, 1200 mg/day and placebo groups, respectively (endpoint analysis). Secondary measures of treatment efficacy also showed that both WS® 5570 groups were statistically superior to placebo. Significantly more patients in the WS® 5570 treatment groups than in the placebo group showed treatment response and remission. WS® 5570 was consistently more effective than placebo in patients with either less severe or more severe baseline impairment. The number of patients who experienced remission was higher in the WS® 5570 1200 mg/day group than the WS® 5570 600 mg/day group. The incidence of adverse events was low in all groups. The adverse event profile was consistent with the known profile for Hypericum extract preparations. Conclusion: Hypericum perforatum extract WS® 5570 at doses of 600 mg/day (once daily) and 1200 mg/day (600 mg twice daily) were found to be safe and more effective than placebo, with comparable efficacy of the WS® 5570 groups for the treatment of mild to moderate major depression.


Related Articles

  • Hyperforin as a natural antidepressant: an overview. Gharge, Deepali; Pavan, Todkar; Sunil, Bavaskar; Dhabale., Pandurang // Journal of Pharmacy Research;Sep2009, Vol. 2 Issue 9, p1373 

    Hyperforin is a structurally novel anti-depressant isolated from Hypericum perforatum commonly known as St.John's wort. Hyperforin belongs to group of compound known as acylphloroglucinols. The peculiarity of Hyperforin is that it is chemically unrelated to synthetic antidepressants. Hyperforin...

  • Wort watch: the evidence. Gunasekara, Sanji // New Zealand Doctor;11/15/2007, p19 

    The article focuses on the efficacy of Saint John's wort extract as treatment for depression. It presents a case study of a 29-year-old mother diagnosed with typical features of depression who decided to try Saint John's wort to treat her condition along with selective serotonin reuptake...

  • Smart Talk on Supplements and Botanicals: The Complexities of Treating Depression. Low Dog, Tieraona // Alternative & Complementary Therapies;Apr2011, Vol. 17 Issue 2, p66 

    An interview with doctor Tieraona Low Dog is presented. When asked on the importance of talking about depression, she says that depression is the main cause of morbidity in the society in which she believes that discussing what composes mental health is important. She states that nutrition plays...

  • Herbal Blues-Beater. Altshul, Sara // Prevention;Jul2005, Vol. 57 Issue 7, p94 

    Offers information about the mood-enhancing properties of the herb Saint John's wort, also know as Hypericum perforatum. Ability of Saint John's wort to heal wounds and heal pain, according to ancient healers; Studies that showed Saint John's wort's ability to ease depression; Statement that...

  • St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Greeson, Jeffrey M.; Sanford, Britt; Monti, Daniel A. // Psychopharmacology;2001, Vol. 153 Issue 4, p402 

    Abstract Rationale: St. John's wort (Hypericum perforatum) has recently gained popularity as an alternative treatment for mild to moderate depression. Given the current widespread use of this herbal remedy, it is important for medical professionals to understand the potential pharmacological...

  • The secrets of Saint-John's-Wort. Tyler, Varro E. // Prevention;Feb97, Vol. 49 Issue 2, p74 

    Looks at the use of Saint-John's-Wort (Hypericum perforatum) for the treatment of mild depression. Beneficial uses; Possible side effects; Where the name Saint-John's-Wort came from; The different ways the herb's multiple compounds work.

  • TREATING DEPRESSION WITH HYPERICUM. Bloomfield, Harold H. // Saturday Evening Post;Nov/Dec97, Vol. 269 Issue 6, p62 

    Argues that the herb known scientifically as Hypericum perforatum may be a medical breakthrough in the treatment of some forms of depression. Public acceptance of depression as an illness; High cost of antidepressant medications; Side effects of antidepressant medications; Use of Hypericum as...

  • St. John's wort: Herbal Prozac.  // Consumer Reports on Health;May98, Vol. 10 Issue 5, p8 

    States that using the St. John's wort,(hypericum perforatum) can be beneficial in treating depression. Reference to the book `Hypericum Depression;' Information on several studies which suugest that St. John's wort can help fight depression; Indication that the United States Food and Drug...

  • Are St John's wort and SSRI antidepressants really ineffective in depression? Sarris, Jerome; Schweitzer, Isaac; Mischoulon, David // Australian Journal of Herbal Medicine;2012, Vol. 24 Issue 4, p118 

    This paper provides a reply to the Wong (AJHM 24:3;97-9) critique of the Rapaport et al (2011) study which found no significant difference between St John's wort, citalopram and placebo in treating minor depression. Additionally we address the reasons why St John's wort and antidepressant...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics